[go: up one dir, main page]

WO2013100660A3 - Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor - Google Patents

Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor Download PDF

Info

Publication number
WO2013100660A3
WO2013100660A3 PCT/KR2012/011631 KR2012011631W WO2013100660A3 WO 2013100660 A3 WO2013100660 A3 WO 2013100660A3 KR 2012011631 W KR2012011631 W KR 2012011631W WO 2013100660 A3 WO2013100660 A3 WO 2013100660A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye
pharmaceutical composition
treatment
synthesis inhibitor
pge2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/011631
Other languages
French (fr)
Korean (ko)
Other versions
WO2013100660A2 (en
Inventor
이형근
심종우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120074204A external-priority patent/KR101373246B1/en
Application filed by Industry Academic Cooperation Foundation of Yonsei University filed Critical Industry Academic Cooperation Foundation of Yonsei University
Priority to JP2014550020A priority Critical patent/JP5870211B2/en
Priority to US14/648,970 priority patent/US9629855B2/en
Publication of WO2013100660A2 publication Critical patent/WO2013100660A2/en
Publication of WO2013100660A3 publication Critical patent/WO2013100660A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition for the treatment of eye pain, containing a PGE2 synthesis inhibitor. The use of the pharmaceutical composition for the prevention or treatment of eye pain according to the present invention, which contains the PGE2 synthesis inhibitor as an active ingredient, makes it possible to alleviate the symptoms of eye pain by selectively inhibiting the PGE2 expression level, and also has the advantages of treating and preventing xerophthalmia and of overcoming and preventing eye discomfort caused by various inflammation-inducing circumstances including following surgery. Also, by using a kit for detecting the amount of PGE2, PGD2 and COX2, the present invention makes it possible to easily diagnose eye-pain symptoms in clinical practice, and can be widely used in checking the state not only of patients having xerophthalmia but also patients following eye surgery.
PCT/KR2012/011631 2011-12-29 2012-12-27 Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor Ceased WO2013100660A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2014550020A JP5870211B2 (en) 2011-12-29 2012-12-27 Pharmaceutical composition for the treatment of ocular pain comprising a PGE2 synthesis inhibitor
US14/648,970 US9629855B2 (en) 2011-12-29 2012-12-27 Pharmaceutical composition for treatment of eye pain, containing PGE2 synthesis inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110146450 2011-12-29
KR10-2011-0146450 2011-12-29
KR10-2012-0074204 2012-07-06
KR1020120074204A KR101373246B1 (en) 2011-12-29 2012-07-06 Pharmaceutical composition for ocular pain comprising PGE2 synthase inhibitor

Publications (2)

Publication Number Publication Date
WO2013100660A2 WO2013100660A2 (en) 2013-07-04
WO2013100660A3 true WO2013100660A3 (en) 2013-10-03

Family

ID=48698750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/011631 Ceased WO2013100660A2 (en) 2011-12-29 2012-12-27 Pharmaceutical composition for treatment of eye pain, containing pge2 synthesis inhibitor

Country Status (1)

Country Link
WO (1) WO2013100660A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187179A4 (en) * 2014-08-28 2018-02-07 Keio University Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US20110281882A1 (en) * 2007-08-10 2011-11-17 Jinzhong Zhang Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US20110281882A1 (en) * 2007-08-10 2011-11-17 Jinzhong Zhang Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BHATTACHERJEE, P. ET AL.: "Inhibition of the prostaglandin synthetase systems in ocular tissues by indomethacin", BR. J. PHARMAC., vol. 50, 1974, pages 227 - 230 *
CHO, HYUNG ET AL.: "Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution", CLINICAL OPHTHALMOLOGY, vol. 3, 2009, pages 199 - 210 *
KULKARNI, P. S. ET AL.: "The effect of intravitreal and topical prostaglandins on intraocular inflammation", INVEST, OPHTHAMOL. VIS. SCI., vol. 23, no. 3, 1982, pages 383 - 392 *

Also Published As

Publication number Publication date
WO2013100660A2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
BR112014008789A2 (en) prevention and treatment of eye conditions
BR112014000380A2 (en) pharmaceutical composition, methods of treatment and uses thereof
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
BR112015009168A2 (en) compound of formula xi, use of a compound, pharmaceutical composition, method of treating a pde4-mediated disease in a subject, method of modulating a pde4-mediated function in a subject, method of achieving an effect in a patient, and method to inhibit pde4
MD20150043A2 (en) Inhibitors of histone demethylases
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
MA33076B1 (en) USE OF A GAMMA SECRETASE INHIBITOR FOR THE TREATMENT OF CANCER
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
UA113849C2 (en) THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN
MX2015011359A (en) Macrocyclic lrrk2 kinase inhibitors.
EA201270071A1 (en) A METHOD OF TREATING A PATIENT NEEDING ASPIRIN TREATMENT
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015012526A (en) Macrocyclic rip2 kinase inhibitors.
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
AR086395A1 (en) PACKAGE FOR TREATMENT OF PATHOLOGIES
MX2009011900A (en) Diabetic wound healing.
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
EA201270449A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH MCP-1
MA33813B1 (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR PARASITIC DISEASE
ECSP088588A (en) USE OF TIOTROPE SALTS IN THE TREATMENT OF PERSISTENT MODERATE ASTHMA
EP4218786A3 (en) Opiorphin for use as analgesic agent
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12863025

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014550020

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 12863025

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14648970

Country of ref document: US